Ronald Loggers (M.Sc., MBA) is a Managing Director and CEO of ISA since June 2013. Prior to that, he was a Managing Director at Multifund B.V., a family-owned investment firm. From 1998 to 2005, he worked for private equity firm HAL Investments and during that period, amongst others, he served on the Supervisory Board of Schreiner Luchtvaart Groep B.V., and as Managing Director for the production and logistics facilities of optical retailer Pearle Benelux. Prior to that, he worked for McKinsey & Company from 1993 until 1998. In 1991/92, he was a manager at the quality control laboratories of Fokker Aircraft’s Ypenburg plant. Mr. Loggers holds an MBA from INSEAD and holds an M.Sc. in Chemical Engineering from Delft University of Technology.
Cornelis Melief has made significant contributions to the field of immunology, in particular cancer immunology. In 1991, he became professor at the LUMC and since then his group has been working intensively to devise new cancer therapies based on the activation of the patient’s own immune system. Before, he headed the immunology department at the Netherlands Cancer Institute (NKI). He started his career at the blood bank in Amsterdam (CLB). Cornelis is member of the Royal Netherlands Academy of Arts and Sciences. He is author of more than 450 peer-reviewed publications and inventor on more than 30 patents and patent applications.
Willem-Jan Krebber has over 15 years of experience in the pharmaceutical and biotechnology industry in various roles covering process development, manufacturing and project management. In his current role as Chief Operating Officer he leads all innovation, product development and manufacturing activities within the company. Prior to ISA Pharmaceuticals, he worked at OctoPlus (now Dr. Reddy’s R&D) as CMC Program Manager where he was responsible for managing OctoPlus own product and technology development programs on advanced drug formulations and delivery. Prior to OctoPlus he held various CMC and project management positions at Crucell (now part of Janssen Vaccines & Prevention and Johnson & Johnson) for the development and manufacturing of cell-based products. Willem-Jan Krebber holds a Masters in Biology from Utrecht University and a Masters in Biotechnology from Delft University of Technology.
Gerben Moolhuizen, Chief Business Development Officer
Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. Prior to ISA Pharmaceuticals, he worked at OctoPlus, where his most recent role was General Manager. He has been closely involved in the company´s fundraising activities, IPO, and the acquisition by Dr. Reddy’s and has also been responsible for the subsequent integration of OctoPlus into Dr. Reddy’s R&D organization. Prior to OctoPlus, Gerben Moolhuizen worked, among others, at Pharming, where he held various roles in business development and product development and was also involved in the company´s IPO in 1998 . He holds an M.Sc. from Utrecht University in Medical Biology and an MBA from Erasmus University Rotterdam.
Richard Stead, M.D., Acting Chief Medical Officer
Richard Stead has more than 25 years experience in the biotechnology and pharmaceutical industry designing and directing clinical trials, as well as preclinical research and development with companies such as Amgen and Immunex. As Principal of BioPharma Consulting Services since 2002, he has been actively involved in the development of a number oncology products including different strategies for cancer immunotherapy. He also serves an independent director on the Boards of Affimed Therapeutics AG and Ascend Biopharmaceuticals.